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Much of the therapeutic beneﬁt of allogeneic transplant is by a graft versus tumor eﬀect. Further data shows that transplant
engraftment is not dependant on myeloablation, instead relying on quantitative competition between donor and host cells. In
the clinical setting, engraftment by competition alone is not feasible due to the need for large numbers of infused cells. Instead,
low-level host irradiation has proven to be an eﬀective engraftment strategy that is stem cell toxic but not myeloablative. The
above observations served as the foundation for clinical trials utilizing allogeneic matched and haploidentical peripheral blood
stem cell infusions with minimal conditioning in patients with refractory malignancies. Although engraftment was transient or
not apparent, there were compelling responses in a heavily pretreated patient population that appear to result from the breaking of
tumorimmunetolerancebythehostthroughtheactionsofIFNγ,invariantNKTcells,CD8Tcells,NKcells,orantigenpresenting
cells.
1.Introduction
Allogeneic marrow transplantation exerts much of its ther-
apeutic eﬀect through graft killing of tumor cells. This was
established in studies of the eﬀect of donor lymphocyte infu-
sions on relapsed chronic myelocytic leukemia (CML) in
marrow transplant patients [1].
Initial insights on the presence of graft versus leukemia
came from the work of Thomas and colleagues [2, 3], show-
ingthatleukemicrelapseswerelowerinallogeneictransplant
patients who had acute and chronic graft-versus-host disease
(GVHD) as compared to those who did not develop these
complications. Furthermore, patients with both acute and
chronic GVHD had lower relapse rates than those with
either acute or chronic GVHD alone [4, 5]. There was an
increased leukemic relapse rate in identical twin marrow
transplants as compared to allogeneic transplants [2, 6]. T-
cell depletion from allogeneic marrow infusions decreased
acute and chronic GVHD, but increased the rate of relapses.
In a similar fashion, cyclosporine immunosuppression after
allogeneic transplantation increased leukemic relapses, and
discontinuation of the drug at the ﬁrst sign of a relapse could
induce a remission [7–9].
The most direct evidence of a cellular immune attack
against leukemic cells was provided by Kolb and colleagues
[1]. They demonstrated high rates of durable remissions in
relapse CML with the simple infusion of donor lymphocytes.
Donor lymphocyte responses after relapse from allogeneic
transplant were also seen in patients with AML, ALL,
MDS, polycythemia vera, lymphoma and myeloma [10,
11]. Thus cellular therapy in patients with a variety of
marrow malignancies has been established and appears to be
mediated by T lymphocytes although other cell types might
also be involved.
2.OriginsofNonmyeloablative
Transplantation
Thesestudiessuggestedthatcellularapproacheswithouttox-
ic myeloablative therapy might be eﬀective treatment for
many marrow malignancies. General dogma had been that
myeloablative treatment was needed to open space so that
marrowcellscouldengraft.However,Micklemetal.,in1968,
demonstrated that engraftment into nonirradiated hosts was
feasible, obtaining up to 8.5% T6T6 donor cells in CBA
host marrow at 3 months after transplantation of 20 million2 Advances in Hematology
marrow cells from normal T6T6 donors [12]. This work was
extended by others [13–15].
The studies by Brecher and colleagues formed the basis
for extensive studies in our laboratory on engraftment into
nonmyeloablated mice, which in turn led to applications of
nonmyeloablated transplantation in humans. Studying male
BALB/c marrow engrafted into female BALB/c mice with no
cytoreductive therapy, we determined that engraftment was
essentially quantitative resulting from competition between
infused cells and host cells. Evaluated mice which had
received 5 consecutive intravenous injections of 40 million
marrow cells showed continued engraftment in marrow at
21–25 months after transplant ranging from 15% to 42%.
Patterns of engraftment were similar for thymus and spleen
[20].Furtherstudiesshowedthathighnumbersofcellsgiven
in one injection gave equal values to engraftment to the same
number of cells divided over multiple injections [21–23].
Critical features of marrow engraftment were approached
by determining total murine marrow cellularity and the
observed engraftment percentages when 40 million marrow
cells were infused (72mice) and comparing those with
theoretical outcomes [24]. Total cellularity in BALB/c mice
was 530 ± 20 million cells, stable from 8 weeks to 1 year of
age. Using this data, a theoretical model of infused marrow
(40 million cells) replacing or adding to host marrow gave
values of 7.5 and 7.0%, respectively; the observed 8-week
engraftment of 40 million male BALB/c marrow cells into
female hosts (72mice) was 6.91 ± 0.4%. This indicated that
syngeneic engraftment was determined solely by stem cell
competition, not by “opening space”. A summary of the
above is depicted in List 1.
List 1: Engraftment Into Normal Untreated Mice.
(i) High levels of chimerism seen in marrow, spleen, and
thymus.
(ii) Chimerism persistent out to 2 years.
(iii) Chimerism was multilineage.
(iv) Alldonorcellsappearedtohavebeenengrafted.Final
readouts were determined by competition between
host and donor cells.
These data also indicated that so-called niches are not
limiting as to engraftment, although there are clearly areas
favoring speciﬁc diﬀerentiation pathways. Most “niche”
studies need to be reconsidered since they have been carried
using a dormant puriﬁed murine marrow stem cells, which
do not appear to be representative of the true marrow long-
term repopulating stem cell.
3. The Role of Reduced IntensityConditioning
These data formed a base for engraftment into non-my-
eloablated mice. However, engraftment into non-myeloab-
lated mice required large number of marrow cells, which
would be diﬃcult to obtain in a clinical setting. Accordingly,
we investigated whether minimal myeloablation with low
d o s e so fi r r a d i a t i o nw o u l db ea ne ﬀective engraftment
strategy [25]. In these studies, we demonstrated that expo-
sure of BALB/c mice to doses of irradiation that cause
minimal myeloablation (50–100cGy) gave high levels of
donor chimerism, such that relatively small numbers of mar-
row cells (10–40 million) can give donor chimerism in the
40–100% range. These doses of irradiation turned out
to be minimally myeloablative but quite stem cell toxic.
Engraftable stem cells measured at 8 weeks after engraftment
from mice exposed to 100cGy whole body irradiation were
reduced to 8.6 ± 3% of marrow from nonirradiated mice. At
6months,thereductionwasstillpresent,21±7%[26].These
data provided us with a stem cell toxic nonmyeloablative
approach for therapeutic transplantation. Engraftment with
reduced intensity conditioning is summarized in List 2.
List 2: Minimal Myeloablation and Engraftment.
(i) 50–100cGy gives relatively high levels of engraftment
with 10–40 million murine marrow cells.
(ii) These levels of irradiation are minimally myelotoxic
with mild eﬀects on blood counts.
(iii) These levels of irradiation are very stem cell toxic.
(iv) A stem cell toxic nonmyeloablative approach poses
interesting therapeutic possibilities.
4. Presence of Engraftment
However, it was not clear if this would hold for allogeneic
engraftment. Accordingly, we investigated engraftment into
non or minimally myeloablated allogeneic mice. We felt that
low-dose irradiation might avoid the cytokine storm which
appeared to be involved in GVHD, and that relatively high
levels of marrow cells might overcome rejection. However,
we found that we could not obtain engraftment using 100–
300cGy and 40 million cells in H-2 mismatched B6.SJL to
BALB/c marrow transplants. Clearly, immune barriers ex-
isted.
W et h e nt r i e da n t i g e np r e e x p o s u r ea n dc o s t i m u l a t i o n
blockade in this setting. Ten million B6.SJL spleen cells were
infused into BALB/c mice 10 days prior to transplantation,
and anti-CD40 ligand antibody was given immediately prior
to the spleen cell infusion and thereafter on days −7, −3, 0,
and +3. On day 0, 40 million B6.SJL whole marrow cells
were infused into the BALB/c hosts which had received
100cGy within 4 hours of marrow infusion. Stable multi-
lineage chimerism at levels between 30–40% was achieved
in the great majority of mice at 1.6mg anti-CD40 ligand
monoclonal antibody per injection out to 64 weeks after
transplantation [27]. There was no GVHD, and mice were
tolerant to donor B6.SJL skin grafts.
We subsequently evaluated whether we could obtain sig-
niﬁcant marrow engraftment in this H-2 mismatched model
by ﬁrst establishing microchimerism to set the stage for
macrochimerism. We showed that establishment of micro-
chimerism (0.5–3.8%) with subsequent infusions of 40 mil-
lionmarrowcellsonweeks12,14,and16orweeks3,4,5,and
6 with injections of anti-CD40 ligand antibody, but without
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engraftment [28]. In the latter schedule, engraftment was
17.9 ± 1.2% at 24 weeks. Thus, we could obtain signiﬁcant
engraftment with scheduled marrow cells and costimulator
blockade. Giving the same number of total cells on day 0 did
not result in signiﬁcant chimerism. Therefore, a scheduling
eﬀect was critical for these results in mismatched allogeneic
murine transplants. These results are diﬀerent from the
results in syngeneic transplants where scheduling appears to
have no eﬀect, rather total cell dose determines engraftment
levels. These studies are summarized in List 3.
List 3: Minimal to No Myeloablation with Mismatched Alloge-
neic Marrow Transplantation.
(i) 100cGy, spleen cell exposure and CD40 ligand anti-
body give signiﬁcant chimerism with 40 million cells
given in one injection.
(ii) A scheduled engraftment with 40 million cells given
multiple times gives signiﬁcant engraftment with
only costimulator blockade.
5.ClinicalTrials
These studies plus the evolving studies on the impact of
donor lymphocyte infusions in clinical transplant set the
stage for human trials using allogeneic or haploidentical
peripheral blood infusions in patients with refractory can-
cers. Patients with refractory cancers were treated with
100cGy total body irradiation followed by infusion of
nonmobilized apheresed allogeneic peripheral blood cells.
Twenty-ﬁve patients were enrolled [29]. Transplants were
with either HLA matched or 1/6 mismatched, one antigen
mismatchedfamilydonors,or4–6/6antigenmatchedumbil-
ical cord blood donor cells. Seven patients with solid tumors
received a sibling transplant and 6 received a cord blood
transplant; none achieved donor chimerism but 1 treated at
thehigher-doselevelof1 ×108 CD3+cells/kghadatransient
nodal response.
Twelve patients with hematologic malignancies were
treated; eleven receiving sibling donor cells. Nine of these
eleven achieved donor chimerism ranging from 5–100%.
In this group, there were four complete remissions and of
these, three had 100% chimerism. Two developed GVHD
with one dying of liver GVHD and the other succumbing to
disease relapse. One patient with AML and 100% chimerism
achieved a complete remission that required reinfusion of
donor cells due to persistent pancytopenia. Interestingly,
another patient with a large cell lymphoma and only
transient 5% chimerism for one week developed a sustained
complete remission for at least 42 months after transplan-
tation. This particular patient was heavily pretreated with
salvage chemotherapy and radiotherapy for relapsed disease
following autologous transplantation. A similar remarkable
responsewasseenwithoutengraftmentinapatientwithCLL
who witnessed a 75% decrease in lymphadenopathy, despite
no evidence of chimerism.
In order to expand donor base, we next evaluated the
safety and eﬃcacy of haploidentical transplantation in a
phase I/II nonimmunosuppressive nonmyeloablative setting
[16]. A total of 41 patients with relapsed refractory cancers
received 100cGy total body irradiation along with an infu-
sion of 1 × 106 to 2 × 108 CD3+ cells per kilogram. Twenty
nine patients received the highest dose of 2 × 108 cells/Kg.
A post-infusional syndrome termed “haploimmunostorm”
was seen at the two highest cell levels. This consisted of
fever with a median onset of 14 hours after cell infusion and
malaise, liver function test alterations, morbilliform rash,
and diarrhea to varying degrees. Skin biopsies were negative
for GVHD. This syndrome rapidly responded to steroid
administrationandwasprobablyavariantofcytokinestorm.
In all, there were 26 patients with hematologic malignan-
cies with 14 responses, 7 of which were major. Two of six
patients with lymphoma remained free of disease at 76 and
82 months, respectively. There were 5 durable complete
responses and 4 partial responses in 13 patients with AML.
All responses occurred outside the donor chimerism with
sensitivity of 1–5% in the chimerism determinations. There
were no responses with the solid tumor patients, and two
patients who converted to total chimerism died, one of
GVHD. Altogether, these results indicated that there was
signiﬁcant antitumor activity in the setting of rejection
of infused marrow cells, some of which were clinically
signiﬁcant. Presently, the mechanisms underlying this are
unclear, but we favor a breaking of host tolerance to tumor
cells. These results are summarized in List 4.
List 4: Allogeneic and Haploidentical Cellular Therapy of
Hematologic Malignancies.
(i) HLA-matched engraftment in nonmyeloablated set-
ting showed tumor responses associated with chim-
erism.
(ii) Haploidentical infusions in nonmyeloablated setting
caused responses in lymphoma and AML patients
without chimerism.
Clearly, nonengraftment (at least maxi-engraftment)
presents a potentially new direction in therapy of refractory
hematologic malignancies. An interesting study from China
[17] in elderly patients indicated that adding haploidentical
cell infusions to chemotherapy markedly improved results
with no GVHD, but with persistent donor microchimerism.
Prolonged survival in patients who do not achieve engraft-
menthasbeenreportedelsewhereinpatientswithacutelym-
phocytic leukemia, non-Hodgkin lymphoma, Hodgkin lym-
phoma, myelodysplastic syndrome, and multiple myeloma
[18, 19].
These results summarized in Table 1 suggest that studies
of hematologic malignancies in which marrow rejection is
the goal are indicated to more fully evaluate both clinical ef-
ﬁcacy and underlying mechanism.
6.ProposedMechanismof Action
Theunderlyingmechanismofcellulartherapyeﬃcacyisonly
recently coming to light and is thought to include everything
from the growth factors employed for cell collection to the
actual composition of the cells themselves. Clearly T cells4 Advances in Hematology
Table 1: Summary of nonengraftment cellular therapy results.
Author Number of patients Conditioning regimen Number of CD3 cells
infused
Response rate
(CR/PR)
Colvin et al. [16] 19 patients (AML/NHL only) 100cGy TBI 1 × 106–2 × 108/kg 37% (26%/11%)
Guo et al. [17] 30 patients (AML)
Mitoxantrone 8–10mg/m2
(3 days) and cytarabine
150mg/m2 (7 days)
0.5–2.6 × 108/kg 80% (80%/NR)
∗O’Donnell et al.
[18] 4 patients (ALL, MDS)
Fludarabine 30mg/m2,
200cGy TBI, Post
transplant ± Pretransplant
cyclophosphamide
2.6–3.8 × 107/kg 75% (75%/0%)
∗Dey et al. [19] 22 patients (NHL, HL, Multiple
Myeloma)
Cyclophosphamide
50mg/kg (3-4 days), ATG
15–30mg/kg (3-4 days),
and anti-CD 2 monoclonal
antibody
1 × 107–2.98 × 108/kg 41% (18%/22%)
∗Only patients who did not engraft in this study are included in the results. AML= acute myeloid leukemia, NHL= non-Hodgkins lymphoma, MDS=
myelodysplastic syndrome, ALL= acute lymphocytic leukemia, HL= Hodgkins lymphoma.
are involved in this process; however, neither the bystander
killing eﬀect nor the T cell receptor cross reactivity to allo-
geneic antigens with tumor antigens is thought to play a role.
Central to the development of a graft versus leukemia or host
versus leukemia response is the underlying regulation be-
tween the development of a TH1 response and a graft or host
versus tumor eﬀect (and with it the potential for acute or
chronic GVHD) and a TH2 response that allows for tolerance
of the graft and prevents GVHD. Clinical trials suggest that
an initial engraftment of donor cells followed by the host
rejection of this engraftment is essential to developing a
host versus tumor response. Based on this concept, Sykes
and colleagues developed a mixed chimeric bone marrow
murine model to more fully understand the mechanism of
this response. The mixed chimera developed represents the
initial infusion and partial engraftment of haploidentical
cells. They are then able to model the rejection of these
haploidentical cells through the infusion of recipient murine
leukocytes (RLI). RLI infusion then induces a host versus
graft(HVG)reactionthatresultsinanantitumorresponseby
the host’s immune system to malignancies present within the
host which they have been able to further characterize. This
response requires a complex interaction between interferon-
γ (IFN-γ), CD8 T cells, invariant NK-T cells (iNKT), NK
cells, and antigen presenting cells.
Early work by this group ﬁrst disclosed the importance
of IFN-γ in the development of an antitumor response. They
further determined that IFN-γ derived from the recipient
was essential for the development of an antitumor response
[30]. Overall, a robust cytokine response was seen clini-
cally when mixed chimerism is lost. Although many other
cytokines are involved in this response, experiments have
shown that IFN-γ generation was crucial for an antitumor
response.IFN-γ isalsoimportantintheallogeneictransplan-
tation graft versus leukemia eﬀect [31]. Later experiments
determined that IFN-γ production initially is through RLI
CD8+ T cells by leukocytes present within the RLI fraction
as well as non RLI recipient leukocytes. The presence of RLI
CD8+ T cells and non RLI recipient CD4+ cells is crucial for
the development of antitumor responses to RLI [32]. Also
involved in the anti-tumor response are recipient iNK-T cells
with the anti-tumor eﬀects of these cells distinct from RLI
CD8+ T cells. Following RLI, iNK-T cells become activated
and in turn activate both recipient NK cells and dendritic
cells[33].Theendtheoreticalresultistheimmuneactivation
and subsequent breaking of host tolerance to tumor.
In addition to the cells themselves, the initial collection
of cells for infusion and methods therein may play a role.
For example, G-CSF has been shown to promote TH2
diﬀerentiation and T regulatory cell proliferation, while also
expanding the pool of immature antigen presenting cells. All
of these measures help prevent the development of GVHD,
while not inhibiting the cytolytic T cell graft versus tumor
eﬀect. A further increase in GVT is seen when G-CSF is
pegylated, which leads to activation of invariant NK cells.
These cells are thought to play a role in the development
of cytotoxic response through cytokine release that leads to
further recruitment of NK cells and CD8+ CTLs [34]. Other
cell types such as CD4+/CD25+ T regulatory cells (T-regs)
have been shown to play a role in the donor and recipient cell
interactions in haploidentical transplant where engraftment
occurs [35, 36]. Tregs appear to have a role in host tolerance
and allow for an increase in engraftment with a decrease in
GvHD. The role Tregs have in the nonengraftment setting is
still unclear.
7. Conclusions
As outlined above, cell infusional treatment of leukemia
and lymphoma is not completely dependent on graft versus
tumor/leukemia eﬀect. Rather, rejection of the graft itself
appears to reeducate the host’s immune system to recognize
the tumor, thereby creating a host versus tumor eﬀect. This
method is not without its side eﬀects in the form of a
cytokine storm involving IFN-γ but does bypass the morbid-
ity and mortality that develop from graft versus host disease.Advances in Hematology 5
An additional advantage of non-engraftment haploidentical
transplantation over allogeneic transplantation is the avail-
ability of donors. Family members are readily identiﬁed as
potential donors making this a readily available treatment
modality. The overall keys to the future of nonengraftment
haploidenticaltransplantationresideinbetterunderstanding
of the degree of chimerism, if any, necessary for a reaction as
well as the timing and role of host eﬀector cell stimulation.
The potential result is the ability to harness the host’s
immune system in order to provide an eﬀective therapeutic
modality toeradicatemalignancy. Futurestudies shouldhelp
deciphertheunderlyinginteractionthatoccursbetweenhost
and donor cells. Key questions that remain are the amount
and type of conditioning regimen as well as the degree
of antigenic mismatch required to stimulate a host versus
tumor response in vitro and in vivo. Potential further clinical
trials could focus on decreasing or eliminating radiation or
chemotherapy conditioning in addition to examining the
eﬀectsofcompleteHLAmismatchinordertofurtherremove
any chance of engraftment and with it GvHD development.
Moreover, future trials may also explore the role of multiple
cellular infusions spaced out in a treatment plan to possibly
elicit a more robust response.
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